RxDoctor Payments Data

Jennifer Hill, MD

Urogynecology and Reconstructive Pelvic Surgery · Riverhead, NYNPI 1932390150

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Axonics, Inc. at 46.6% of the total. 2025 is the largest year on record at $5,286, 8.7 times the $605 reported in 2019.

$12,725in general payments, 2019–2025

Across 118 payments — averaging $107.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$6K
  • Boston Scientific$5K
  • Astellas Pharma US Inc$677
  • Intuitive Surgical$220
  • Caldera Medical, Inc$107
  • Boehringer Ingelheim$97
  • plus $266 from 11 others

What the payments were for

  • Speaking & faculty fees$5,25841%
  • Travel & lodging$3,01124%
  • Food & beverage$4,05132%
  • Education$2992%
  • Gifts$1071%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,725 in reported general payments places this provider in the 85th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.

See all urogynecology and reconstructive pelvic surgery providers in New York

Medicare billing

Part B allowed, 2024
$54,605
Medicare patients
161
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron112$107,007
MyrbetriqMirabegron55$63,725
Estradiol143$11,574
EstringEstradiol15$7,925
Mirabegron ErMirabegron11$6,798
Solifenacin Succinate34$3,888
Desmopressin Acetate23$3,346
CefuroximeCefuroxime Axetil89$2,012
Estradiol (Twice Weekly)Estradiol12$1,711
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst50$1,414
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav51$1,053
Tamsulosin Hcl46$1,013
ProgesteroneProgesterone, Micronized17$772
Clobetasol Propionate21$620
Oxybutynin Chloride ErOxybutynin Chloride24$615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$45$107,007112 claims
Astellas Pharma US IncMyrbetriq$677$63,72555 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.

Other urogynecology and reconstructive pelvic surgery in Riverhead

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →